Jaume Mora, MD, PhD: Naxitamab Approval for High-Risk Neuroblastoma in the Bone or Bone Marrow

Recently, the FDA approved naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow. In this interview, Jaume Mora, MD, PhD, Scientific Director of Oncology and Hematology at Sant Joan de Déu Barcelona Children's Hospital and lead investigator of one of the trials on which the approval was based, speaks with i3 Health about the benefits of naxitamab for patients with relapsed/r...

Continue reading

Naxitamab Plus GM-CSF Approved For R/R High-Risk Neuroblastoma in Bone or Bone Marrow

The FDA has approved naxitamab (Danyelza®, Y-mAbs Therapeutics, Inc.) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged one year and older and for adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have experienced a partial or minor response to prior therapy, or who have stable disease. The approval was based on two open-label clinical trials, Study 201 and Study 12-230. "Neuroblastoma is a rare cancer but r...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.